Option and Evaluation Agreements in Pharma and Biotech

401 views

Published on

Report description The Option and Evaluation Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies.This report provides details of the latest option and evaluation agreements announced in the pharmaceutical and biotechnology sectors. Detailed and comprehensive, the report provides details of option and evaluation agreements from 2003 to end 2008. The report provides a detailed understand and analysis of how and why companies enter option and evaluation deals. The majority of deals are option agreements whereby one party to the agreement obtains an option right from the other party.Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered ' contract documents provide this insight where press releases and databases do not. This report contains over 400 links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by pharma/biotech companies and their partners.Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities. Chapter 1 provides a brief introduction to the report, whilst chapter 2 provides an analysis of the trends in option and evaluation as well as a discussion on the merits of each type of deal. Chapter 3 provides an overview of the structure of option and evaluation deals. The chapter includes numerous case studies to enable understanding of both option and evaluation deals where partnering or acquisition is the primary focus of the agreement. Chapter 4 provides a review of the leading option and evaluation deals since 2000. Deals are listed by headline value and most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary including option and evaluation frequency followed by a comprehensive listing of option and evaluation contract documents available in the public domain. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive listing of all option and evaluation agreement contracts available in the public domain, respectively. The chapter is organized by A-Z company name, option/evaluation type, therapy area and stage of development at signing. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Key benefitsOption and Evaluation Agreements in Pharma and Biotech provides the reader with the following key benefits:In-depth understanding of option and evaluation deal trends since 2000 Analysis of the structure of option and evaluation agreements with numerous real life case studies Comprehensive access to over 400 actual option and evaluation contracts entered into by the world's biopharma companies Detailed access to actual option and evaluation contracts enter into by the leading fifty bigpharma companies Insight into the terms included in a option and evaluation agreement, together with real world clause examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of

Published in: Business, News & Politics
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
401
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Option and Evaluation Agreements in Pharma and Biotech

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Option and Evaluation Agreements in Pharma and BiotechPublished on March 2009 Report SummaryReport descriptionThe Option and Evaluation Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedentedaccess to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies.This report provides details of the latest option and evaluation agreements announced in the pharmaceutical and biotechnologysectors. Detailed and comprehensive, the report provides details of option and evaluation agreements from 2003 to end 2008.The report provides a detailed understand and analysis of how and why companies enter option and evaluation deals. The majority ofdeals are option agreements whereby one party to the agreement obtains an option right from the other party.Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process interms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of thepayments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight wherepress releases and databases do not.This report contains over 400 links to online copies of actual option and evaluation contract documents as submitted to the SecuritiesExchange Commission by pharma/biotech companies and their partners.Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of importantissues, many of which will have a significant impact on each partys ability to derive value from the deal.The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities. Chapter 1provides a brief introduction to the report, whilst chapter 2 provides an analysis of the trends in option and evaluation as well as adiscussion on the merits of each type of deal.Chapter 3 provides an overview of the structure of option and evaluation deals. The chapter includes numerous case studies toenable understanding of both option and evaluation deals where partnering or acquisition is the primary focus of the agreement.Chapter 4 provides a review of the leading option and evaluation deals since 2000. Deals are listed by headline value and most activebigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary including option and evaluationfrequency followed by a comprehensive listing of option and evaluation contract documents available in the public domain. Each dealtitle links via Weblink to an online version of the actual contract document, providing easy access to each contract document ondemand.Chapter 6 provides a comprehensive listing of all option and evaluation agreement contracts available in the public domain,respectively. The chapter is organized by A-Z company name, option/evaluation type, therapy area and stage of development atsigning. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contractOption and Evaluation Agreements in Pharma and Biotech Page 1/8
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statisticsdocument on demand.Key benefitsOption and Evaluation Agreements in Pharma and Biotech provides the reader with the following key benefits:In-depth understanding of option and evaluation deal trends since 2000Analysis of the structure of option and evaluation agreements with numerous real life case studiesComprehensive access to over 400 actual option and evaluation contracts entered into by the worlds biopharma companiesDetailed access to actual option and evaluation contracts enter into by the leading fifty bigpharma companiesInsight into the terms included in a option and evaluation agreement, together with real world clause examplesUnderstand the key deal terms companies have agreed in previous dealsUndertake due diligence to assess suitability of your proposed deal terms for partner companiesReport scopeOption and Evaluation Agreements in Pharma and Biotech is intended to provide the reader with an in-depth understanding of theoption and evaluation trends and structure of deals entered into by leading biopharma companies worldwide.Option and Evaluation Agreements in Pharma and Biotech includes:Trends in option and evaluation dealmaking in the biopharma industry since 2000Analysis of option and evaluation deal structureCase studies of real-life option and evaluation dealsAccess to over 400 option and evaluation contract documentsThe leading option and evaluation deals by value since 2000Most active option and evaluation dealmakers since 2000The leading option and evaluation partnering resourcesIn Option and Evaluation Agreements in Pharma and Biotech, the available contracts are listed by:A-ZHeadline valueOption typeStage of development at signingTherapeutic areaEach deal title links via Weblink to an online version of the actual contract document, providing easy access to each contractdocument on demand. Table of ContentExecutive SummaryChapter 1 IntroductionChapter 2 Trends in option and evaluation dealmaking2.1. Introduction2.2. Difference between option and evaluation dealsOption and Evaluation Agreements in Pharma and Biotech Page 2/8
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics2.2.1. Types of option agreement2.3. Trends in option/evaluation deals since 20002.4. Co-promotion options2.4.1. Attributes of co-promotion in multi-component deals2.4.2. Reasons for including co-promotion options in a deal2.4.3. Uptake of co-promotion rights2.4.4. Co-promotion rights as bargaining chips2.4.5. The future of co-promotion as part of multicomponent deals2.5. Company acquisition options2.5.1. Case study 1: Cephalon Ception January 20092.5.2. Case study 2: Endo Indevus January 20092.5.3. The future of option to acquireChapter 3 Overview of option and evaluation deal structure3.1. Introduction3.2. Evaluation agreement structure3.2.1. Example evaluation agreements3.2.1.a. Case study 3: BioGenerix Neose January 20053.3. Option agreement structure3.3.1. Example option agreements3.3.1.a. Option to licenseCase study 4: GlaxoSmithKline Regulus Therapeutics April 20083.3.1.b. Option to extend/expand applications/territoriesCase study 5: Salix Dr Falk April 20073.3.1.c. Option to financeCase study 6: Merck KgaA Archemix June 20073.3.1.d. Option to co-promoteCase study 7: Novartis Anadys June 20053.3.1.e. Option to manufacture/supplyCase study 8: NPS Allelix Nycomed July 20073.4. Option to acquire agreement structure3.4.1. Example acquisition option clauses3.4.1.a. Case study 9: MGI Pharma AkaRx October 20073.4.1.b. Case study 10: Abbott Ibis Biosciences Isis Pharmaceuticals January 2008Chapter 4 Leading option and evaluation deals4.1. Introduction4.2. Top partnering deals incorporated an option clause by value4.3. Bigpharma option deal activityChapter 5 Bigpharma option and evaluation agreements5.1. Introduction5.2. How to use option/evaluation agreements5.3. Company option and evaluation agreement listingsAbbottActavisAlcon LabsOption and Evaluation Agreements in Pharma and Biotech Page 3/8
  4. 4. Find Industry reports, Company profilesReportLinker and Market StatisticsAllerganAmgenAstellasAstraZenecaBarrBaxter InternationalBayerBiogen IdecBoehringer IngelheimBristol-Myers SquibbChugaiCSLDaiichi SankyoEisaiEli LillyForest LaboratoriesGenentechGenzymeGilead SciencesGlaxoSmithKlineJohnson & JohnsonKingLundbeckMenariniMerck & CoMerck KGaAMitsubishi TanabeMundipharmaNovartisNovo NordiskNycomed PharmaOtsukaPfizerProcter & GambleRatiopharmaRocheSanofi-AventisSchering PloughServierShireSolvayStadaTakedaTevaUCBWatsonWyethChapter 6 Option and evaluation agreement directory 2003-8Option and Evaluation Agreements in Pharma and Biotech Page 4/8
  5. 5. Find Industry reports, Company profilesReportLinker and Market Statistics6.1. Introduction6.2. Company A-Z6.3. Deals by typeAcquisitionCo-developmentCo-marketingCo-promotionEvaluationExtensionFinancingLicensingMarketingSupply6.4. Deals by stageDiscoveryPreclinicPhase IPhase IIPhase IIIRegulatoryMarketedFormulation6.2. Deals by therapyCardiovascularCentral Nervous SystemDermatologyGastrointestinalGenitourinaryHematologyHormonalImmunologyInfectionInflammationMetabolicMusculoskeletalOncologyOphthalmicRespiratoryDeliveryAppendicesAppendix 1 Option/evaluation referencesAppendix 2 ResourcesAppendix 3 Deal type definitionsAppendix 4 Example M&A option contract documentAppendix 5 - Example option partnering contract documentAbout CurrentPartneringTABLE OF FIGURESFigure 1: Definition of option and evaluationOption and Evaluation Agreements in Pharma and Biotech Page 5/8
  6. 6. Find Industry reports, Company profilesReportLinker and Market StatisticsFigure 2: Types of option rightFigure 3: Trends in option/evaluation deal announcements, 2000-2008Figure 4: Option/evaluation deals signed at each phase of development, 2000-2008Figure 5: Example deals where co-promotion options have been actively exercised, since 2000Figure 6: Recent option to acquire dealsFigure 7: Components of the evaluation deal structureFigure 8: Types of option in an agreementFigure 9: Attributes of option terms:Figure 10: Top 25 partnering deals incorporating an option/evaluation clause by value since 2000Figure 11: Bigpharma top 50 option deals since 2003Figure 12: Online partnering resourcesFigure 13: Deal type definitionsFigure 14: Option for M&A agreement between Abbott Molecular Isis Pharmaceuticals Ibis Biosciences January 2005Figure 15: Option in partnering agreement between Array Biopharma Celgene September 2007Option and Evaluation Agreements in Pharma and Biotech Page 6/8
  7. 7. Find Industry reports, Company profilesReportLinker and Market Statistics Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Option and Evaluation Agreements in Pharma and Biotech Product Formats Please select the product formats and the quantity you require. Unknown / error--USD 1 447.44 Quantity: _____ 1 User License--USD 1 447.44 Quantity: _____ CD-ROM--USD 3 185.85 Quantity: _____ Hard Copy--USD 3 185.85 Quantity: _____ Corporate License--USD 5 789.75 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Option and Evaluation Agreements in Pharma and Biotech Page 7/8
  8. 8. Find Industry reports, Company profilesReportLinker and Market Statistics Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Option and Evaluation Agreements in Pharma and Biotech Page 8/8

×